Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 3:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 1,228 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: HAV Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age

NCT00197002
View directory record Official record
Conditions
Hepatitis A
Interventions
GSK Biologicals 2-dose inactivated hepatitis A vaccine (Havrix), Prevnar™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 13 Months
Enrollment
521 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
18
States / cities
Centennial, Colorado • Bardstown, Kentucky • Louisville, Kentucky + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 29, 2026, 3:23 AM EDT
Completed Phase 2 Interventional Results available

Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients

NCT01054729
View directory record Official record
Conditions
Hepatitis C
Interventions
Sofosbuvir, Placebo, PEG, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
San Francisco, California • Gainesville, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Oct 29, 2026, 3:23 AM EDT
Completed Phase 3 Interventional

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

NCT01804829
View directory record Official record
Conditions
Hepatitis C Infection, Viruses, Hepatocellular Carcinoma, Hepatitis, Viral, Human, Liver Cirrhosis
Interventions
Civacir® 10%
Biological
Lead sponsor
Biotest Pharmaceuticals Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
23
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 29, 2026, 3:23 AM EDT
Completed Not applicable Interventional

Electronic Record Assimilation and Subsequent Eradication of Hepatitis C

NCT04873609
View directory record Official record
Conditions
Hepatitis C, Liver Diseases
Interventions
Patient portal message
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
54 Years to 74 Years
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 29, 2026, 3:23 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Staged Phase I/II Hepatitis C Prophylactic Vaccine

NCT01436357
View directory record Official record
Conditions
Hepatitis C
Interventions
AdCh3NSmut1, MVA-NSmut, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
548 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
5
States / cities
San Francisco, California • Baltimore, Maryland • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 29, 2026, 3:23 AM EDT
Completed Phase 1 Interventional

Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients

NCT00426712
View directory record Official record
Conditions
Hepatitis B
Interventions
1018 ISS immunostimulatory oligonucleotide with HBV surface antigen, Hepatitis B Vaccine (Recombinant)
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
40 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
4
States / cities
Costa Mesa, California • Brooklyn Center, Minnesota • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 29, 2026, 3:23 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV

NCT05904470
View directory record Official record
Conditions
Chronic Hepatitis C Virus, Hepatitis C, Chronic, Hepatitis C, Hepatic Cirrhosis, HCV
Interventions
Bemnifosbuvir, Ruzasvir
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 29, 2026, 3:23 AM EDT
Completed Phase 1Phase 2 Interventional

Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects

NCT01445795
View directory record Official record
Conditions
Hepatitis C
Interventions
200 mg INX-08189 Fasted, Placebo QD Fasted, 100 mg INX-08189 QD, Placebo QD, 100 mg INX-08189 with low-fat meal, Placebo with low-fat meal, 100 mg INX-08189 BID Fasted, Placebo BID Fasted, ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Oct 29, 2026, 3:23 AM EDT
Completed Phase 2 Interventional Results available

Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection

NCT01713283
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Oct 29, 2026, 3:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Pentavalent DTaP-Hep B-IPV

NCT00133445
View directory record Official record
Conditions
Diphtheria, Hepatitis B, Poliomyelitis, Pertussis, Tetanus
Interventions
DTaP-Hep B-IPV Vaccine, Monovalent Hep B Vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 5 Days
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Oct 29, 2026, 3:23 AM EDT
Not listed Phase 1 Interventional

Therapeutic Hepatitis C Virus Vaccine

NCT04318379
View directory record Official record
Conditions
Chronic Hepatitis C Infection
Interventions
HCVax
Biological
Lead sponsor
GeneCure Biotechnologies
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 29, 2026, 3:23 AM EDT
Completed Not applicable Interventional

Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV Drugs

NCT00257127
View directory record Official record
Conditions
HIV Infections
Interventions
Pneumococcal 7-valent conjugate vaccine, Pneumococcal polysaccharide vaccine, Hepatitis B vaccine, Measles, mumps, and rubella virus vaccine, live
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 23 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
24
States / cities
Birmingham, Alabama • Alhambra, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 29, 2026, 3:23 AM EDT
Not listed No phase listed Observational

Impact of DAA Uptake in Controlling HCV Epidemic and Modeling Interventions for HCV Elimination Among HIV-infected Persons in San Diego

NCT03551002
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic, HIV/AIDS
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 29, 2026, 3:23 AM EDT
Completed Phase 3 Interventional

Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)

NCT01573351
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Asunaprevir, Daclatasvir, Peg-interferon Alfa-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
20
States / cities
Montgomery, Alabama • La Jolla, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 29, 2026, 3:23 AM EDT
Completed Phase 1Phase 2 Interventional

Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor

NCT04596475
View directory record Official record
Conditions
Hepatitis C, Hepatitis C Virus Infection, Response to Therapy of
Interventions
glecaprevir/pibrentasvir (GLE/PIB)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 29, 2026, 3:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment

NCT04971928
View directory record Official record
Conditions
Hepatitis B
Interventions
GSK3228836
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Oct 29, 2026, 3:23 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

HBRN: Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B

NCT01298037
View directory record Official record
Conditions
Hepatitis B
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2026
U.S. locations
11
States / cities
San Francisco, California • Boston, Massachusetts • Plymouth, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 29, 2026, 3:23 AM EDT
Completed No phase listed Observational

Genetics of Hepatitis C Virus Infection

NCT00005657
View directory record Official record
Conditions
Hepatitis C, Liver Disease
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 29, 2026, 3:23 AM EDT
Terminated Phase 3 Interventional Results available

Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C

NCT01500772
View directory record Official record
Conditions
Hepatitis C
Interventions
Alisporivir, Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
26
States / cities
Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Oct 29, 2026, 3:23 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

NCT06824194
View directory record Official record
Conditions
Pneumococcal Immunization
Interventions
PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, Rotarix, RotaTeq, Vaxelis vaccine, Varivax, Priorix, VAQTA, Havrix
Biological
Lead sponsor
Sanofi
Industry
Eligibility
42 Days to 89 Days
Enrollment
2,360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
103
States / cities
Birmingham, Alabama • Guntersville, Alabama • Oneonta, Alabama + 81 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 29, 2026, 3:23 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B

NCT00116805
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
TDF, ADV, TDF placebo, ADV placebo, FTC/TDF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 69 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
20
States / cities
Orange, California • Pasadena, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 29, 2026, 3:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV

NCT00001119
View directory record Official record
Conditions
HIV Infections
Interventions
Tetanus Toxoid Vaccine, Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Abacavir sulfate, Amprenavir, Efavirenz, Hepatitis B Vaccine (Recombinant), Lamivudine, Zidovudine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
288 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1999
U.S. locations
11
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2011 · Synced Oct 29, 2026, 3:23 AM EDT
Completed No phase listed Observational

Prevention of Recurrent Hepatitis B After Liver Transplantation

NCT00059267
View directory record Official record
Conditions
Hepatitis B, Cirrhosis, Acute Liver Failure, Hepatocellular Carcinoma
Interventions
HBIG, Epivir, Hepsera
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
13 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 29, 2026, 3:23 AM EDT
Completed Phase 3 Interventional

Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)

NCT01581203
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Asunaprevir (ASV), Daclatasvir (DCV), Pegylated-interferon alfa 2a (PegIFN), Ribavirin (RBV)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
748 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
18
States / cities
Montgomery, Alabama • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 29, 2026, 3:23 AM EDT